Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C28H38N4O6 |
| Molecular Weight | 526.6245 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OCC(C)(C)CN3CCN(CC=C)CC3
InChI
InChIKey=QBTSPDQKRVMTRU-UHFFFAOYSA-N
InChI=1S/C28H38N4O6/c1-7-11-30-12-14-31(15-13-30)17-28(4,5)18-38-27(34)24-20(3)29-19(2)23(26(33)37-6)25(24)21-9-8-10-22(16-21)32(35)36/h7-10,16,25,29H,1,11-15,17-18H2,2-6H3
| Molecular Formula | C28H38N4O6 |
| Molecular Weight | 526.6245 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Iganidipin is a new dihydropiridynic derivative of calcium antagonist. It is the only currently available calcium antagonist in the form of ophthalmic solution. Its topical administration increases ipsilateral optic nerve head blood flow in rabbits and monkeys and inhibits the contraction of blood vessels induced by endothelin -1. Iganidipin is also used for treat Angina pectoris and Hypertension.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:25:21 GMT 2025
by
admin
on
Tue Apr 01 16:25:21 GMT 2025
|
| Record UNII |
ZU9QD72G5Z
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ZU9QD72G5Z
Created by
admin on Tue Apr 01 16:25:21 GMT 2025 , Edited by admin on Tue Apr 01 16:25:21 GMT 2025
|
PRIMARY | |||
|
788791-04-8
Created by
admin on Tue Apr 01 16:25:21 GMT 2025 , Edited by admin on Tue Apr 01 16:25:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER | |||
|
|
ENANTIOMER -> ENANTIOMER |
|
